Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of HULL ASSOCIATES LLC and Ironstone Product Development (IPD) with a view toward addressing MedTech’s emerging priorities in regulatory and reimbursement and building scale to offer thoughtful strategies and differentiated project delivery for all product categories.
Headquartered in Boston, Massachusetts, HULL ASSOCIATES LLC is a leading strategic market access and reimbursement consultancy firm specialized in achieving market access for medical device, diagnostic, and specialty pharma products in all major global markets, including United States, Europe, Latin America, Japan, India, and China. HULL ASSOCIATES LLC has in-country experts who are specialized in market access, offering both technical knowledge and relationships to achieve results. The core focus areas for the business include strategic services such as market access & reimbursement assessments; evidence planning; data analytics & health economics; pricing analysis; assessment & validation of clinical trial designs; as well as in-country post-launch services to support coverage, coding, and payment in all the global markets.
Founded by Joel Ironstone in 2013 and headquartered in Toronto, Canada, IPD has been focused on assisting clients with all aspects of medical and health product development and commercialization which directly aligns with Avania’s vision. The core focus areas for the business are early product development, quality, and strategic regulatory with projects in the areas of medical robotics and surgical navigation, AI/machine learning, imaging, respiratory devices, IVDs, and wearables. This acquisition will strengthen Avania’s position in these product categories, further advancing Avania’s leadership in this space.
The combined organization offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs).
“The addition of HULL ASSOCIATES and IPD furthers our vision of becoming a trusted global partner for the MedTech community, advancing innovations from bench to bedside, improving patient outcomes globally,” said Sapna Hornyak, president and CEO of Avania, “and will provide us with enhanced capabilities to bring comprehensive, highly customized solutions to every partnership as we continue to lead the MedTech CRO segment as a preferred life cycle partner.”
Avania customers will benefit from an expanded roster of subject matter experts in the global pre-clinical, clinical (in vitro diagnostics, artificial intelligence/machine learning, and software as medical device), regulatory, and market access consulting space.